Who
Gregory Bailey
Director
Company insider
Files Form 4 as: Director, Serina Therapeutics; Director, Biohaven; Director, Biohaven Pharmaceutical Holding Co; Director, Medivation; Director, Opexa Therapeutics.
In numbers
- Trades disclosed
- 199
- Buys
- 27
- Sells
- 53
- Bought
- $18.7M
- Sold
- $62.1M
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 25 Apr 2006
- Last trade
- 17 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 22 Jun 2026 | SER Serina TherapeuticsBiotechnology | SEC FORM 4 Code C | $4.0M1,770,805 at $2.25 | filing |
| 17 Jun 2026filed 22 Jun 2026 | SER Serina TherapeuticsBiotechnology | SEC FORM 4 Code C | $15.0M6,666,667 at $2.25 | filing |
| 17 Jun 2026filed 22 Jun 2026 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,250 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,250 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,333,333 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | $1.7M762,548 at $2.25 | filing |
| 17 Jun 2026filed 22 Jun 2026 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,333,333 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | $1.7M762,548 at $2.25 | filing |
| 17 Jun 2026filed 22 Jun 2026 | SER Serina TherapeuticsBiotechnology | SEC FORM 4 Code C | $4.0M1,770,805 at $2.25 | filing |
| 17 Jun 2026filed 22 Jun 2026 | SER Serina TherapeuticsBiotechnology | SEC FORM 4 Code C | $15.0M6,666,667 at $2.25 | filing |
| 28 Apr 2026filed 30 Apr 2026 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —68,693 at $0.00 | filing |
| 28 Apr 2026filed 30 Apr 2026 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —68,693 at $0.00 | filing |
| 31 Mar 2026filed 21 Apr 2026 | SER Serina TherapeuticsBiotechnology | SEC FORM 4 Code A | $116K59,667 at $1.94 | filing |
| 31 Mar 2026filed 21 Apr 2026 | SER Serina TherapeuticsBiotechnology | SEC FORM 4 Code A | $116K59,667 at $1.94 | filing |
| 13 Nov 2025filed 17 Nov 2025 | BHVN BiohavenBiotechnology | SEC FORM 4 Bought | $3.0M400,000 at $7.50 | filing |
| 7 Nov 2025filed 10 Nov 2025 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 5 May 2025filed 7 May 2025 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,716 at $0.00 | filing |
| 8 Apr 2025filed 10 Apr 2025 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $3.9M762,548 at $5.18 | filing |
| 17 Dec 2024filed 19 Dec 2024 | SER Serina TherapeuticsBiotechnology | SEC FORM 4 Bought | $18K3,866 at $4.59 | filing |
| 24 Sep 2024filed 25 Sep 2024 | BHVN BiohavenBiotechnology | SEC FORM 4 Bought | $221K5,000 at $44.19 | filing |
News
Biohaven Stock Soars Nearly 30% After FDA Accepts Resubmitted Application for Rare Disease Drug VyglxiaBHVN · ibtimes.com.au · 22 Oct 2026Ono Pharma Announces an Exclusive License Agreement with Biohaven to Develop and Commercialize IgG Degraders in... - Pharma / BioTech / Nutrition - ONO Pharmaceutical Co., LtdBHVN · newswiretoday.com · 9 Oct 2026
0 headlines in the last 90 days name Gregory Bailey; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.